Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With Obesity

Inclusion Criteria: 1. Adults aged 18 to 75 years. 2. Diagnosed with simple obesity, defined as BMI ≥ 30 kg/m². 3. Have not used any anti-obesity medications (including GLP-1 RAs, tirzepatide, metformin for weight loss, etc.) within the past 3 months. 4. Able and willing to comply with study procedures and complete follow-up assessments. 5. Provide written informed consent. Exclusion Criteria: 1. Presence of secondary obesity (e.g., endocrine disorders such as Cushing's syndrome or hypothyroidism). 2. Use of anti-obesity medications or participation in another weight-loss program within the past 3 months. 3. Diagnosed type 1 or type 2 diabetes mellitus requiring hypoglycemic drug therapy. 4. History of pancreatitis, severe gastrointestinal disease, or bariatric surgery. 5. Severe cardiovascular, hepatic, renal, or psychiatric disease that may affect participation. 6. Pregnant or breastfeeding women, or women planning pregnancy during the study period. 7. Current participation in any other clinical trial. 8. Any condition that, in the investigator's judgment, makes the participant unsuitable for the study.